Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer

Matteo Santoni, Simon J. Crabb, Alessandro Conti, Lorena Rossi, Luciano Burattini, Vincenza Conteduca, Caroline Chau, Salvatore L. Burgio, Giovanni Muzzonigro, Stefano Cascinu, Ugo De Giorgi

Research output: Contribution to journalArticlepeer-review


Abstract Background Measures of prognosis for cancer patients are typically evaluated at the time of diagnosis. However, this study assessed the changes in 2-year CS rates after first-line chemotherapy for metastatic UC. Patients and Methods Conditional overall survival and CPFS probability were estimated using the Kaplan-Meier method. Adjusted survival functions were stratified according to age groups (<70 years vs. ≥ 70 years), sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS; ECOG PSA ≤ 2 vs. ECOG PS > 2), pretreatment Hb levels (<12 mg/dL vs. ≥ 12 mg/dL) and pretreatment NLR (<3 vs. ≥ 3). Pairs of CS curves were compared using the Mantel-Haenszel log-rank test. Results Two hundred ninety-eight patients were included in this analysis, 233 were male, and their median age was 69 years. First-line median overall survival and progression-free survival were 10.7 months (95% confidence interval [CI], 9.6-12.6) and 6.0 months (95% CI, 5.5-7.1), respectively. CPFS and COS showed an increasing trend in the population considered (b = 0.35; P

Original languageEnglish
Article number333
Pages (from-to)244-249
Number of pages6
JournalClinical Genitourinary Cancer
Issue number3
Publication statusPublished - Jun 1 2015


  • Advanced urothelial cancer
  • Conditional Survival
  • Overall survival
  • Prognosis
  • Progression-free survival

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer'. Together they form a unique fingerprint.

Cite this